Patent · US Active

Respiratory syncytial virus vaccine

US10117926B2 · kind B2 · utility

2Cited by

2References

15Claims

0Family size

Assignees

VIB VZW · BE
UNIVERSITEIT GENT · BE

Inventors

Xavier Saelens · Ieper, BE
Bert Schepens · Evergem, BE
Walter Fiers · Laarne, BE

Key dates

Filing date	Jun 29, 2016
Grant date	Nov 6, 2018
Priority date	—
Expiry date	Jun 29, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2760/18571
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Described is a vaccine against Respiratory Syncytial Virus (RSV). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the RSV-encoded Small Hydrophobic (SH) protein. The ectodomain of SH is referred to as SHe. The ectodomain is typically presented as an oligomer, or pentamer. Further described are antibodies, raised against the ectodomain or specific for the ectodomain, and their use for protecting a subject against RSV infection and/or for treatment of an infected subject.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.